MedTrace Logo

A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284

NCT06884098 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-20

No results posted yet for this study

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.

Conditions

  • Primary Hypercholesterolaemia

Interventions

DRUG

AD-228B

AD-228B, 1Tab., Per Oral

DRUG

AD-2284

AD-2284, 1Tab., Per Oral

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-10
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06884098 on ClinicalTrials.gov